| 1 |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021，71(3): 209-249.
|
| 2 |
Zeng H, Chen W, Zheng R, et al. Changing cancer survival in china during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018，6(5): 555-567.
|
| 3 |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中国实用外科杂志，2020，40(2): 121-138.
|
| 4 |
中华医学会感染病学分会．慢性乙型肝炎防治指南(2019年版)[J]. 中华肝脏病杂志，2019，27(12): 938-961.
|
| 5 |
中国抗癌协会肝癌专业委员会．中国肝癌多学科综合治疗专家共识[J]. 临床肝胆病杂志，2021，37(2): 278-285.
|
| 6 |
中华预防医学会肿瘤预防与控制专业委员会感染相关肿瘤防控学组，中华预防医学会慢病预防与控制分会，中华预防医学会健康传播分会．中国肝癌一级预防专家共识(2018) [J]．中华预防医学杂志，2019，4(1): 36-44.
|
| 7 |
Mak LY, Cruz-Ramón V, Chinchilla-López P, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma[J]. Am Soc Clin Oncol Educ Book，2018，38(4): 262-279.
|
| 8 |
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors[J]. J Hepatol，2008，48(2): 335-352.
|
| 9 |
Chu CM, Liaw YF. Hepatitis b virus-related cirrhosis: natural history and treatment[J]. Semin Liver Dis，2006，26(2): 142-152.
|
| 10 |
McMahon BJ, Holck P, Bulkow L, et al. Serologic and clinical outcomes of 1536 alaska natives chronically infected with hepatitis b virus[J]. Ann Intern Med，2001，135(9): 759-768.
|
| 11 |
Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis b surface antigen levels help predict disease progression in patients with low hepatitis b virus loads[J]. Hepatology，2013，57(2): 441-450.
|
| 12 |
Tseng TC, Liu CJ, Hsu CY, et al. High level of hepatitis b core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic hbv infection of intermediate viral load[J]. Gastroenterology，2019，157(6): 1518-1529.
|
| 13 |
An P, Xu J, Yu Y, et al. Host and viral genetic variation in hbv-related hepatocellular carcinoma[J]. Front Genet，2018，9(5): 261.
|
| 14 |
Ning Q, Han M, Sun Y, et al. Switching from entecavir to pegifn alfa-2a in patients with hbeag-positive chronic hepatitis b: a randomised open-label trial (osst trial) [J]. J Hepatol，2014，61(4): 777-784.
|
| 15 |
Hu P, Shang J, Zhang W, et al. Hbsag loss with peg-interferon alfa-2a in hepatitis b patients with partial response to nucleos(t)ide analog: new switch study[J]. J Clin Transl Hepatol，2018，6(1): 25-34.
|
| 16 |
王贵强，王福生，成军，等．慢性乙型肝炎防治指南(2015更新版)[J]．中华肝脏病杂志，2015，23(12): 888-905.
|
| 17 |
Lampertico P, Agarwal K, Berg T, et al. EAsl 2017 clinical practice guidelines on the management of hepatitis b virus infection[J]. J Hepatol，2017，67(2): 370-398.
|
| 18 |
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis b: aasld 2018 hepatitis b guidance[J]. Hepatology，2018，67(4): 1560-1599.
|
| 19 |
中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 中华肝脏病杂志，2019, 27(8): 594-603.
|
| 20 |
Chan HLY, Chan FWS, Hui AJ, et al. Switching to peginterferon for chronic hepatitis b patients with hepatitis b e antigen seroconversion on entecavir-a prospective study[J]. J Viral Hepat, 2019，26(1): 126-135.
|
| 21 |
Kumada T, Toyoda H, Tada T, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis b patients: a propensity score analysis[J]. J Hepatol，2013，58(3): 427-433.
|
| 22 |
Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis b virus infection[J]. Hepatology，2013，58(1): 98-107.
|
| 23 |
Liu K, Choi J, Le A, et al. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis b patients with cirrhosis[J]. Aliment Pharmacol Ther，2019，50(9): 1037-1048.
|
| 24 |
Ikeda K, Saitoh S, Suzuki Y, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis b virus: a pilot study[J]. Cancer，1998，82(5): 827-835.
|
| 25 |
Jiang XY, Huang B, Huang DP, et al. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis b virus patients without antiviral therapy[J]. World J Gastroenterol，2021，27(11): 1101-1116.
|
| 26 |
Chen CF, Lee WC, Yang HI, et al. Changes in serum levels of hbv dna and alanine aminotransferase determine risk for hepatocellular carcinoma[J]. Gastroenterology，2011，141(4): 1240-1248.
|
| 27 |
Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis b: a nationwide cohort study[J]. Gastroenterology，2014，147(1): 143-151.
|
| 28 |
Zhang W, Wang X, Wang Y, et al. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis b: results of a 10-year follow up[J]. Medicine (Baltimore)，2017，96(44): 8454-8454.
|
| 29 |
Cho JY, Paik YH, Sohn W, et al. Patients with chronic hepatitis b treated with oral antiviral therapy retain a higher risk for hcc compared with patients with inactive stage disease[J]. Gut, 2014，63(12): 1943-1950.
|
| 30 |
Zhou TC, Lai X, Feng MH, et al. Systematic review and meta-analysis: development of hepatocellular carcinoma in chronic hepatitis b patients with hepatitis e antigen seroconversion[J]. J Viral Hepat，2018，25(1): 1172-1179.
|
| 31 |
Yip TC, Chan HL, Wong VW, et al. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis b surface antigen seroclearance[J]. J Hepatol，2017，67(5): 902-908.
|
| 32 |
Yip TC, Wong GL, Chan HL, et al. Hbsag seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues[J]. J Hepatol, 2019，70(3): 361-370.
|
| 33 |
Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis b and advanced liver disease[J]. N Engl J Med，2004，351(15): 1521-1531.
|
| 34 |
Choi J, Kim HJ, Lee J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis b: a korean nationwide cohort study[J]. JAMA Oncol，2019，5(1): 30-36.
|
| 35 |
Hou JL, Zhao W, Lee C, et al. Outcomes of long-term treatment of chronic hbv infection with entecavir or other agents from a randomized trial in 24 countries[J]. Clin Gastroenterol Hepatol, 2020，18(2): 457-467.
|
| 36 |
Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue[J]. Antimicrob Agents Chemother，2005，49(5): 1898-1906.
|
| 37 |
Kim SU, Seo YS, Lee HA, et al. Hepatocellular carcinoma risk steadily persists over time despite long-term antiviral therapy for hepatitis b: a multicenter study[J]. Cancer Epidemiol Biomarkers Prev，2020，29(4): 832-837.
|
| 38 |
Liang KH, Hsu CW, Chang ML, et al. Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis b[J]. J Infect Dis，2016，213(6): 966-974.
|
| 39 |
Ren P, Cao Z, Mo R, et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing hbv-related hepatocellular carcinoma for chronic hepatitis b patients at high risk[J]. Expert Opin Biol Ther，2018，18(10): 1085-1094.
|
| 40 |
龚文锋，陆世东，钟鉴宏，等. 术前抗病毒治疗对HBV-DNA阴性肝细胞癌患者术后病毒再激活及肝功能的影响[J]. 中国肿瘤临床，2016，43(15): 668-673.
|
| 41 |
Chong CC, Wong GL, Lai PB. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis b-related hepatocellular carcinoma[J]. World J Gastroenterol，2014，20(20): 6006-6012.
|
| 42 |
Heimbach JK, Kulik LM, Finn RS, et al. AAsld guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology，2018，67(1): 358-380.
|
| 43 |
Huang G, Lai EC, Lau WY, et al. Posthepatectomy hbv reactivation in hepatitis b-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low hbv-dna levels[J]. Ann Surg，2013，257(3): 490-505.
|
| 44 |
Wang Z, Duan Y, Zhang J, et al. Preoperative antiviral therapy and microvascular invasion in hepatitis b virus-related hepatocellular carcinoma: a meta-analysis[J]. Eur J Pharmacol, 2020，883(5): 173382-173382.
|
| 45 |
Sohn W, Paik YH, Kim JM, et al. Hbv dna and hbsag levels as risk predictors of early and late recurrence after curative resection of hbv-related hepatocellular carcinoma[J]. Ann Surg Oncol, 2014，21(7): 2429-2435.
|
| 46 |
Bozza C, Cinausero M, Iacono D, et al. Hepatitis b and cancer: a practical guide for the oncologist[J]. Crit Rev Oncol Hematol，2016，98(5): 137-146.
|
| 47 |
Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis b virus reactivation in patients with lymphoma and resolved hepatitis b[J]. J Clin Oncol，2013，31(22): 2765-2772.
|
| 48 |
Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis b virus-related hepatocellular carcinoma recurrence following liver resection[J]. Jama，2012，308(18): 1906-1914.
|
| 49 |
Qi W, Zhang Q, Xu Y, et al. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-hbv efficacy and long-term survival among hbv dna-positive hepatocellular carcinoma patients after hepatectomy/ablation[J]. J Viral Hepat, 2020，27(4): 387-396.
|
| 50 |
Sarin SK, Kumar M, Lau GK, et al. Asian-pacific clinical practice guidelines on the management of hepatitis b: a 2015 update[J]. Hepatol Int，2016，10(1): 1-98.
|
| 51 |
Jeng WJ, Chen YC, Chien RN, et al. Incidence and predictors of hepatitis b surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis b e antigen-negative chronic hepatitis b[J]. Hepatology，2018，68(2): 425-434.
|
| 52 |
Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of hbsag in hbeag-negative patients with chronic hepatitis b who stop long-term treatment with adefovir[J]. Gastroenterology，2012，143(3): 629-636.
|
| 53 |
Chen CH, Hung CH, Wang JH, t al. Long-term incidence and predictors of hepatitis b surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis b patients[J]. Clin Microbiol Infect，2018，24(9): 997-1003.
|
| 54 |
Liu F, Liu ZR, Li T, et al. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis b according to their pretreatment hepatitis b e antigen status[J]. J Dig Dis，2018，19(9): 561-571.
|
| 55 |
Wong JS, Wong GL, Tsoi KK, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis b-related hepatocellular carcinoma[J]. Aliment Pharmacol Ther，2011，33(10): 1104-1112.
|
| 56 |
Della Corte C, Nobili V, Comparcola D, et al. Management of chronic hepatitis b in children: an unresolved issue[J]. J Gastroenterol Hepatol，2014，29(5): 912-919.
|
| 57 |
张文宏，张大志，窦晓光，等. 聚乙二醇干扰素α治疗慢性乙型肝炎专家共识[J]. 中华肝脏病杂志，2017，25(9): 678-686.
|
| 58 |
Dong Y, Li M, Zhu S, et al. De novo combination antiviral therapy in e antigen-negative chronic hepatitis B virus-infected paediatric patients with advanced fibrosis[J]. J Viral Hepat, 2020，27: 1338-1343.
|
| 59 |
Konopnicki D, Mocroft A, Wit S, et al. Hepatitis b and hiv: prevalence, aids progression, response to highly active antiretroviral therapy and increased mortality in the eurosida cohort[J]. Aids，2005，19(6): 593-601.
|
| 60 |
Thio CL. Hepatitis b and human immunodeficiency virus coinfection[J]. Hepatology, 2009，49(5): 138-145.
|
| 61 |
Thio CL, Seaberg EC, Skolasky RJ, et al. Hiv-1, hepatitis b virus, and risk of liver-related mortality in the multicenter cohort study (MACS)[J]. Lancet，2002，360(9349): 1921-1926.
|
| 62 |
Maponga TG, Glashoff RH, Vermeulen H, et al. Hepatitis b virus-associated hepatocellular carcinoma in south africa in the era of hiv[J]. BMC Gastroenterol，2020，20(1): 226-226.
|
| 63 |
Wandeler G, Mauron E, Atkinson A, et al. Incidence of hepatocellular carcinoma in hiv/hbv-coinfected patients on tenofovir therapy: relevance for screening strategies[J]. J Hepatol, 2019，71(2): 274-280.
|
| 64 |
Liu WR, Tian MX, Jin L, et al. High levels of hepatitis b surface antigen are associated with poorer survival and early recurrence of hepatocellular carcinoma in patients with low hepatitis b viral loads[J]. Ann Surg Oncol，2015，22(3): 843-850.
|
| 65 |
肝细胞癌抗病毒治疗专家组，吴孟超，汤钊猷，等. HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J]. 实用肝脏病杂志，2014，17(4): 1-6.
|
| 66 |
Katz LH, Paul M, Guy DG, et al. Prevention of recurrent hepatitis b virus infection after liver transplantation: hepatitis b immunoglobulin, antiviral drugs, or both. systematic review and meta-analysis[J]. Transpl Infect Dis，2010，12(4): 292-308.
|
| 67 |
Fox AN, Terrault NA. The option of hbig-free prophylaxis against recurrent hbv[J]. J Hepatol, 2012，56(5): 1189-1197.
|
| 68 |
申川. 中国肝移植术后原发病复发诊疗规范(2019版)[J/CD]. 中华移植杂志(电子版), 2019, 13(4): 21-25.
|
| 69 |
Nasir M, Wu GY. Prevention of hbv recurrence after liver transplant: a review[J]. J Clin Transl Hepatol，2020，8(2): 150-160.
|